 | • レポートコード：MRC2-11QY03885 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、131ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は骨髄異形成症候群のグローバル市場について調査・分析したレポートです。種類別（アルキル化剤、細胞毒性抗生物質、トポイソメラーゼ阻害剤、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別骨髄異形成症候群の競争状況、市場シェア ・世界の骨髄異形成症候群市場：種類別市場規模 2015年-2020年（アルキル化剤、細胞毒性抗生物質、トポイソメラーゼ阻害剤、その他） ・世界の骨髄異形成症候群市場：種類別市場規模予測 2021年-2026年（アルキル化剤、細胞毒性抗生物質、トポイソメラーゼ阻害剤、その他） ・世界の骨髄異形成症候群市場：用途別市場規模 2015年-2020年（病院、クリニック） ・世界の骨髄異形成症候群市場：用途別市場規模予測 2021年-2026年（病院、クリニック） ・北米の骨髄異形成症候群市場分析：米国、カナダ ・ヨーロッパの骨髄異形成症候群市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの骨髄異形成症候群市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の骨髄異形成症候群市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの骨髄異形成症候群市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Celgene、Novartis、Otsuka、Actinium Pharmaceuticals、Acceleron Pharma、Bellicum Pharmaceuticals、Cornerstone Pharmaceuticals、CTI BioPharma、Onconova Therapeutics、Strategia Therapeutics、KaloBios Pharmaceuticals、Kiadis Pharma、Mirati Therapeutics、Astex、Celator Pharmaceuticals、Eli-lilly、Sunesis Pharmaceuticals、Targazyme、Gamida Cell、GlaxoSmithKline、Sumitomo Dainippon Pharma、TetraLogic Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Myelodysplastic Syndrome Market
The global Myelodysplastic Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Myelodysplastic Syndrome Scope and Market Size
Myelodysplastic Syndrome market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myelodysplastic Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Celgene
Novartis
Otsuka
Actinium Pharmaceuticals
Acceleron Pharma
Bellicum Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Onconova Therapeutics
Strategia Therapeutics
KaloBios Pharmaceuticals
Kiadis Pharma
Mirati Therapeutics
Astex
Celator Pharmaceuticals
Eli-lilly
Sunesis Pharmaceuticals
Targazyme
Gamida Cell
GlaxoSmithKline
Sumitomo Dainippon Pharma
TetraLogic Pharmaceuticals
Market segment by Type, the product can be split into
Alkylating Agents
Cytotoxic Antibiotics
Topoisomerase Inhibitors
Others
Market segment by Application, split into
Hospital
Clinic
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myelodysplastic Syndrome Revenue
1.4 Market by Type
1.4.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Alkylating Agents
1.4.3 Cytotoxic Antibiotics
1.4.4 Topoisomerase Inhibitors
1.4.5 Others
1.5 Market by Application
1.5.1 Global Myelodysplastic Syndrome Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome Market Perspective (2015-2026)
2.2 Global Myelodysplastic Syndrome Growth Trends by Regions
2.2.1 Myelodysplastic Syndrome Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myelodysplastic Syndrome Historic Market Share by Regions (2015-2020)
2.2.3 Myelodysplastic Syndrome Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Myelodysplastic Syndrome Market Growth Strategy
2.3.6 Primary Interviews with Key Myelodysplastic Syndrome Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome Players by Market Size
3.1.1 Global Top Myelodysplastic Syndrome Players by Revenue (2015-2020)
3.1.2 Global Myelodysplastic Syndrome Revenue Market Share by Players (2015-2020)
3.1.3 Global Myelodysplastic Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myelodysplastic Syndrome Market Concentration Ratio
3.2.1 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Revenue in 2019
3.3 Myelodysplastic Syndrome Key Players Head office and Area Served
3.4 Key Players Myelodysplastic Syndrome Product Solution and Service
3.5 Date of Enter into Myelodysplastic Syndrome Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Myelodysplastic Syndrome Historic Market Size by Type (2015-2020)
4.2 Global Myelodysplastic Syndrome Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Myelodysplastic Syndrome Market Size by Application (2015-2020)
5.2 Global Myelodysplastic Syndrome Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Myelodysplastic Syndrome Market Size (2015-2020)
6.2 Myelodysplastic Syndrome Key Players in North America (2019-2020)
6.3 North America Myelodysplastic Syndrome Market Size by Type (2015-2020)
6.4 North America Myelodysplastic Syndrome Market Size by Application (2015-2020)
7 Europe
7.1 Europe Myelodysplastic Syndrome Market Size (2015-2020)
7.2 Myelodysplastic Syndrome Key Players in Europe (2019-2020)
7.3 Europe Myelodysplastic Syndrome Market Size by Type (2015-2020)
7.4 Europe Myelodysplastic Syndrome Market Size by Application (2015-2020)
8 China
8.1 China Myelodysplastic Syndrome Market Size (2015-2020)
8.2 Myelodysplastic Syndrome Key Players in China (2019-2020)
8.3 China Myelodysplastic Syndrome Market Size by Type (2015-2020)
8.4 China Myelodysplastic Syndrome Market Size by Application (2015-2020)
9 Japan
9.1 Japan Myelodysplastic Syndrome Market Size (2015-2020)
9.2 Myelodysplastic Syndrome Key Players in Japan (2019-2020)
9.3 Japan Myelodysplastic Syndrome Market Size by Type (2015-2020)
9.4 Japan Myelodysplastic Syndrome Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Myelodysplastic Syndrome Market Size (2015-2020)
10.2 Myelodysplastic Syndrome Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myelodysplastic Syndrome Market Size by Type (2015-2020)
10.4 Southeast Asia Myelodysplastic Syndrome Market Size by Application (2015-2020)
11 India
11.1 India Myelodysplastic Syndrome Market Size (2015-2020)
11.2 Myelodysplastic Syndrome Key Players in India (2019-2020)
11.3 India Myelodysplastic Syndrome Market Size by Type (2015-2020)
11.4 India Myelodysplastic Syndrome Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Myelodysplastic Syndrome Market Size (2015-2020)
12.2 Myelodysplastic Syndrome Key Players in Central & South America (2019-2020)
12.3 Central & South America Myelodysplastic Syndrome Market Size by Type (2015-2020)
12.4 Central & South America Myelodysplastic Syndrome Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Celgene
13.1.1 Celgene Company Details
13.1.2 Celgene Business Overview
13.1.3 Celgene Myelodysplastic Syndrome Introduction
13.1.4 Celgene Revenue in Myelodysplastic Syndrome Business (2015-2020))
13.1.5 Celgene Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Myelodysplastic Syndrome Introduction
13.2.4 Novartis Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Otsuka
13.3.1 Otsuka Company Details
13.3.2 Otsuka Business Overview
13.3.3 Otsuka Myelodysplastic Syndrome Introduction
13.3.4 Otsuka Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.3.5 Otsuka Recent Development
13.4 Actinium Pharmaceuticals
13.4.1 Actinium Pharmaceuticals Company Details
13.4.2 Actinium Pharmaceuticals Business Overview
13.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Introduction
13.4.4 Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.4.5 Actinium Pharmaceuticals Recent Development
13.5 Acceleron Pharma
13.5.1 Acceleron Pharma Company Details
13.5.2 Acceleron Pharma Business Overview
13.5.3 Acceleron Pharma Myelodysplastic Syndrome Introduction
13.5.4 Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.5.5 Acceleron Pharma Recent Development
13.6 Bellicum Pharmaceuticals
13.6.1 Bellicum Pharmaceuticals Company Details
13.6.2 Bellicum Pharmaceuticals Business Overview
13.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Introduction
13.6.4 Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.6.5 Bellicum Pharmaceuticals Recent Development
13.7 Cornerstone Pharmaceuticals
13.7.1 Cornerstone Pharmaceuticals Company Details
13.7.2 Cornerstone Pharmaceuticals Business Overview
13.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Introduction
13.7.4 Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.7.5 Cornerstone Pharmaceuticals Recent Development
13.8 CTI BioPharma
13.8.1 CTI BioPharma Company Details
13.8.2 CTI BioPharma Business Overview
13.8.3 CTI BioPharma Myelodysplastic Syndrome Introduction
13.8.4 CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.8.5 CTI BioPharma Recent Development
13.9 Onconova Therapeutics
13.9.1 Onconova Therapeutics Company Details
13.9.2 Onconova Therapeutics Business Overview
13.9.3 Onconova Therapeutics Myelodysplastic Syndrome Introduction
13.9.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.9.5 Onconova Therapeutics Recent Development
13.10 Strategia Therapeutics
13.10.1 Strategia Therapeutics Company Details
13.10.2 Strategia Therapeutics Business Overview
13.10.3 Strategia Therapeutics Myelodysplastic Syndrome Introduction
13.10.4 Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2015-2020)
13.10.5 Strategia Therapeutics Recent Development
13.11 KaloBios Pharmaceuticals
10.11.1 KaloBios Pharmaceuticals Company Details
10.11.2 KaloBios Pharmaceuticals Business Overview
10.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Introduction
10.11.4 KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.11.5 KaloBios Pharmaceuticals Recent Development
13.12 Kiadis Pharma
10.12.1 Kiadis Pharma Company Details
10.12.2 Kiadis Pharma Business Overview
10.12.3 Kiadis Pharma Myelodysplastic Syndrome Introduction
10.12.4 Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.12.5 Kiadis Pharma Recent Development
13.13 Mirati Therapeutics
10.13.1 Mirati Therapeutics Company Details
10.13.2 Mirati Therapeutics Business Overview
10.13.3 Mirati Therapeutics Myelodysplastic Syndrome Introduction
10.13.4 Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.13.5 Mirati Therapeutics Recent Development
13.14 Astex
10.14.1 Astex Company Details
10.14.2 Astex Business Overview
10.14.3 Astex Myelodysplastic Syndrome Introduction
10.14.4 Astex Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.14.5 Astex Recent Development
13.15 Celator Pharmaceuticals
10.15.1 Celator Pharmaceuticals Company Details
10.15.2 Celator Pharmaceuticals Business Overview
10.15.3 Celator Pharmaceuticals Myelodysplastic Syndrome Introduction
10.15.4 Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.15.5 Celator Pharmaceuticals Recent Development
13.16 Eli-lilly
10.16.1 Eli-lilly Company Details
10.16.2 Eli-lilly Business Overview
10.16.3 Eli-lilly Myelodysplastic Syndrome Introduction
10.16.4 Eli-lilly Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.16.5 Eli-lilly Recent Development
13.17 Sunesis Pharmaceuticals
10.17.1 Sunesis Pharmaceuticals Company Details
10.17.2 Sunesis Pharmaceuticals Business Overview
10.17.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Introduction
10.17.4 Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.17.5 Sunesis Pharmaceuticals Recent Development
13.18 Targazyme
10.18.1 Targazyme Company Details
10.18.2 Targazyme Business Overview
10.18.3 Targazyme Myelodysplastic Syndrome Introduction
10.18.4 Targazyme Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.18.5 Targazyme Recent Development
13.19 Gamida Cell
10.19.1 Gamida Cell Company Details
10.19.2 Gamida Cell Business Overview
10.19.3 Gamida Cell Myelodysplastic Syndrome Introduction
10.19.4 Gamida Cell Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.19.5 Gamida Cell Recent Development
13.20 GlaxoSmithKline
10.20.1 GlaxoSmithKline Company Details
10.20.2 GlaxoSmithKline Business Overview
10.20.3 GlaxoSmithKline Myelodysplastic Syndrome Introduction
10.20.4 GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.20.5 GlaxoSmithKline Recent Development
13.21 Sumitomo Dainippon Pharma
10.21.1 Sumitomo Dainippon Pharma Company Details
10.21.2 Sumitomo Dainippon Pharma Business Overview
10.21.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Introduction
10.21.4 Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.21.5 Sumitomo Dainippon Pharma Recent Development
13.22 TetraLogic Pharmaceuticals
10.22.1 TetraLogic Pharmaceuticals Company Details
10.22.2 TetraLogic Pharmaceuticals Business Overview
10.22.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Introduction
10.22.4 TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020)
10.22.5 TetraLogic Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Myelodysplastic Syndrome Key Market Segments
Table 2. Key Players Covered: Ranking by Myelodysplastic Syndrome Revenue
Table 3. Ranking of Global Top Myelodysplastic Syndrome Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Myelodysplastic Syndrome Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Alkylating Agents
Table 6. Key Players of Cytotoxic Antibiotics
Table 7. Key Players of Topoisomerase Inhibitors
Table 8. Key Players of Others
Table 9. Global Myelodysplastic Syndrome Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Myelodysplastic Syndrome Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Myelodysplastic Syndrome Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Myelodysplastic Syndrome Market Share by Regions (2015-2020)
Table 13. Global Myelodysplastic Syndrome Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Myelodysplastic Syndrome Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Myelodysplastic Syndrome Market Growth Strategy
Table 19. Main Points Interviewed from Key Myelodysplastic Syndrome Players
Table 20. Global Myelodysplastic Syndrome Revenue by Players (2015-2020) (Million US$)
Table 21. Global Myelodysplastic Syndrome Market Share by Players (2015-2020)
Table 22. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome as of 2019)
Table 23. Global Myelodysplastic Syndrome by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Myelodysplastic Syndrome Product Solution and Service
Table 26. Date of Enter into Myelodysplastic Syndrome Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 29. Global Myelodysplastic Syndrome Market Size Share by Type (2015-2020)
Table 30. Global Myelodysplastic Syndrome Revenue Market Share by Type (2021-2026)
Table 31. Global Myelodysplastic Syndrome Market Size Share by Application (2015-2020)
Table 32. Global Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 33. Global Myelodysplastic Syndrome Market Size Share by Application (2021-2026)
Table 34. North America Key Players Myelodysplastic Syndrome Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Myelodysplastic Syndrome Market Share (2019-2020)
Table 36. North America Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 37. North America Myelodysplastic Syndrome Market Share by Type (2015-2020)
Table 38. North America Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 39. North America Myelodysplastic Syndrome Market Share by Application (2015-2020)
Table 40. Europe Key Players Myelodysplastic Syndrome Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Myelodysplastic Syndrome Market Share (2019-2020)
Table 42. Europe Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Myelodysplastic Syndrome Market Share by Type (2015-2020)
Table 44. Europe Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Myelodysplastic Syndrome Market Share by Application (2015-2020)
Table 46. China Key Players Myelodysplastic Syndrome Revenue (2019-2020) (Million US$)
Table 47. China Key Players Myelodysplastic Syndrome Market Share (2019-2020)
Table 48. China Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 49. China Myelodysplastic Syndrome Market Share by Type (2015-2020)
Table 50. China Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 51. China Myelodysplastic Syndrome Market Share by Application (2015-2020)
Table 52. Japan Key Players Myelodysplastic Syndrome Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Myelodysplastic Syndrome Market Share (2019-2020)
Table 54. Japan Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Myelodysplastic Syndrome Market Share by Type (2015-2020)
Table 56. Japan Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Myelodysplastic Syndrome Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Myelodysplastic Syndrome Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Myelodysplastic Syndrome Market Share (2019-2020)
Table 60. Southeast Asia Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Myelodysplastic Syndrome Market Share by Type (2015-2020)
Table 62. Southeast Asia Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Myelodysplastic Syndrome Market Share by Application (2015-2020)
Table 64. India Key Players Myelodysplastic Syndrome Revenue (2019-2020) (Million US$)
Table 65. India Key Players Myelodysplastic Syndrome Market Share (2019-2020)
Table 66. India Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 67. India Myelodysplastic Syndrome Market Share by Type (2015-2020)
Table 68. India Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 69. India Myelodysplastic Syndrome Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Myelodysplastic Syndrome Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Myelodysplastic Syndrome Market Share (2019-2020)
Table 72. Central & South America Myelodysplastic Syndrome Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Myelodysplastic Syndrome Market Share by Type (2015-2020)
Table 74. Central & South America Myelodysplastic Syndrome Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Myelodysplastic Syndrome Market Share by Application (2015-2020)
Table 76. Celgene Company Details
Table 77. Celgene Business Overview
Table 78. Celgene Product
Table 79. Celgene Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 80. Celgene Recent Development
Table 81. Novartis Company Details
Table 82. Novartis Business Overview
Table 83. Novartis Product
Table 84. Novartis Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 85. Novartis Recent Development
Table 86. Otsuka Company Details
Table 87. Otsuka Business Overview
Table 88. Otsuka Product
Table 89. Otsuka Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 90. Otsuka Recent Development
Table 91. Actinium Pharmaceuticals Company Details
Table 92. Actinium Pharmaceuticals Business Overview
Table 93. Actinium Pharmaceuticals Product
Table 94. Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 95. Actinium Pharmaceuticals Recent Development
Table 96. Acceleron Pharma Company Details
Table 97. Acceleron Pharma Business Overview
Table 98. Acceleron Pharma Product
Table 99. Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 100. Acceleron Pharma Recent Development
Table 101. Bellicum Pharmaceuticals Company Details
Table 102. Bellicum Pharmaceuticals Business Overview
Table 103. Bellicum Pharmaceuticals Product
Table 104. Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 105. Bellicum Pharmaceuticals Recent Development
Table 106. Cornerstone Pharmaceuticals Company Details
Table 107. Cornerstone Pharmaceuticals Business Overview
Table 108. Cornerstone Pharmaceuticals Product
Table 109. Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 110. Cornerstone Pharmaceuticals Recent Development
Table 111. CTI BioPharma Business Overview
Table 112. CTI BioPharma Product
Table 113. CTI BioPharma Company Details
Table 114. CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 115. CTI BioPharma Recent Development
Table 116. Onconova Therapeutics Company Details
Table 117. Onconova Therapeutics Business Overview
Table 118. Onconova Therapeutics Product
Table 119. Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 120. Onconova Therapeutics Recent Development
Table 121. Strategia Therapeutics Company Details
Table 122. Strategia Therapeutics Business Overview
Table 123. Strategia Therapeutics Product
Table 124. Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 125. Strategia Therapeutics Recent Development
Table 126. KaloBios Pharmaceuticals Company Details
Table 127. KaloBios Pharmaceuticals Business Overview
Table 128. KaloBios Pharmaceuticals Product
Table 129. KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 130. KaloBios Pharmaceuticals Recent Development
Table 131. Kiadis Pharma Company Details
Table 132. Kiadis Pharma Business Overview
Table 133. Kiadis Pharma Product
Table 134. Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 135. Kiadis Pharma Recent Development
Table 136. Mirati Therapeutics Company Details
Table 137. Mirati Therapeutics Business Overview
Table 138. Mirati Therapeutics Product
Table 139. Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 140. Mirati Therapeutics Recent Development
Table 141. Astex Company Details
Table 142. Astex Business Overview
Table 143. Astex Product
Table 144. Astex Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 145. Astex Recent Development
Table 146. Celator Pharmaceuticals Company Details
Table 147. Celator Pharmaceuticals Business Overview
Table 148. Celator Pharmaceuticals Product
Table 149. Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 150. Celator Pharmaceuticals Recent Development
Table 151. Eli-lilly Company Details
Table 152. Eli-lilly Business Overview
Table 153. Eli-lilly Product
Table 154. Eli-lilly Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 155. Eli-lilly Recent Development
Table 156. Sunesis Pharmaceuticals Company Details
Table 157. Sunesis Pharmaceuticals Business Overview
Table 158. Sunesis Pharmaceuticals Product
Table 159. Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 160. Sunesis Pharmaceuticals Recent Development
Table 161. Targazyme Company Details
Table 162. Targazyme Business Overview
Table 163. Targazyme Product
Table 164. Targazyme Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 165. Targazyme Recent Development
Table 166. Gamida Cell Company Details
Table 167. Gamida Cell Business Overview
Table 168. Gamida Cell Product
Table 169. Gamida Cell Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 170. Gamida Cell Recent Development
Table 171. GlaxoSmithKline Company Details
Table 172. GlaxoSmithKline Business Overview
Table 173. GlaxoSmithKline Product
Table 174. GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 175. GlaxoSmithKline Recent Development
Table 176. Sumitomo Dainippon Pharma Company Details
Table 177. Sumitomo Dainippon Pharma Business Overview
Table 178. Sumitomo Dainippon Pharma Product
Table 179. Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 180. Sumitomo Dainippon Pharma Recent Development
Table 181. TetraLogic Pharmaceuticals Company Details
Table 182. TetraLogic Pharmaceuticals Business Overview
Table 183. TetraLogic Pharmaceuticals Product
Table 184. TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2015-2020) (Million US$)
Table 185. TetraLogic Pharmaceuticals Recent Development
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelodysplastic Syndrome Market Share by Type: 2020 VS 2026
Figure 2. Alkylating Agents Features
Figure 3. Cytotoxic Antibiotics Features
Figure 4. Topoisomerase Inhibitors Features
Figure 5. Others Features
Figure 6. Global Myelodysplastic Syndrome Market Share by Application: 2020 VS 2026
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Myelodysplastic Syndrome Report Years Considered
Figure 10. Global Myelodysplastic Syndrome Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Myelodysplastic Syndrome Market Share by Regions: 2020 VS 2026
Figure 12. Global Myelodysplastic Syndrome Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Myelodysplastic Syndrome Market Share by Players in 2019
Figure 15. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome Revenue in 2019
Figure 17. North America Myelodysplastic Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Myelodysplastic Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Myelodysplastic Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Myelodysplastic Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Myelodysplastic Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Myelodysplastic Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Myelodysplastic Syndrome Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
骨髄異形成症候群（MDS）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Therapeutics Market The global Myelodysplastic Syndrome (MDS) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Myelodysplastic Syndrome (M…- 多嚢胞性卵巣症候群治療の世界市場（～2026年） Polycystic ovary syndrome is a set of symptoms due to elevated androgens in females. Signs and symptoms of polycystic ovary syndrome nclude irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant and patches of thick, darker, velv…
- バーター症候群治療薬の世界市場（～2026年） Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. Market Analysis and Insights: Global Bartter Syndrome Drugs Market The global Bartter Syndrome Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% d…
- バーター症候群治療の世界市場（～2026年） Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. The global market for Bartter syndrome treatment is expected to witness a moderate growth rate over the forecast period. Market Analysis and Insights: Global Bartter Syndrome Treatment Market The global Bart…
- クッシング症候群治療の世界市場（～2026年） Cushing's syndrome involves symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most Cushing's syndrome cases are caused by pituitary adenoma, and multiple endocrine neoplasia. In terms of…